Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01538667
First received: February 21, 2012
Last updated: August 20, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to characterize variability and extent of the deposition of ciprofloxacin in the respiratory tract of healthy subjects in comparison to patients with chronic lung diseases after inhalation of a single 50 mg dry powder dose containing 32 mg active substance. In addition the safety and pharmacokinetics of ciprofloxacin will be evaluated. In this study the radiolabeled substance will be administered and scintigraphy imaging techniques will be used to demonstrate the lung deposition visually. In the healthy subjects an additional pharmacokinetic method is used to calculate lung deposition indirectly based on pharmacokinetic data derived from plasma. For this purpose they will inhale at a separate occasion another dose of ciprofloxacin after having ingested activated charcoal. The latter serves to bind ciprofloxacin which is swallowed down during the inhalation maneuver in the gastrointestinal (GI) tract, thus preventing its uptake into the blood (charcoal block). Safety investigations will focus on local tolerability in the lung.

Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug.

Results from this study will be used to show how the drug is distributed in the human lung.


Condition Intervention Phase
Respiratory System
Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-blinded, Single Dose, Single Centre Trial to Assess the Pulmonary Deposition as Well as Pharmacokinetics, Safety and Tolerability of 99mTc Labeled Ciprofloxacin When Delivered as a Single Dose From a Dry Powder Inhaler to Healthy Subjects With and Without Charcoal Block and Patients Suffering From Bronchiectasis and COPD

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Ciprofloxacin pharmacokinetics including lung deposition [ Time Frame: Within 24 hours after treatment ] [ Designated as safety issue: No ]
    Firstly, scintigraphic imaging, a non-invasive method using a radioactive (99mTc-) label tagged to the formulation, will be used to describe the distribution and deposition of a single inhaled dose of Ciprofloxacin Dry Powder Inhalation (DPI) in the lung quantitatively. Secondly, based on blood sampling over a period of 24 hours after inhalation non-compartmental pharmacokinetic parameters of ciprofloxacin will be calculated to determine the systemic exposure to drug following inhalation of a single 32.5 mg Ciprofloxacin dose.


Secondary Outcome Measures:
  • Adverse Events collection [ Time Frame: Within 30 days ] [ Designated as safety issue: Yes ]

Enrollment: 24
Study Start Date: April 2012
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
Experimental: Arm 2 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
Experimental: Arm 3 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
Experimental: Arm 4 Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939)
50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Inclusion criteria for all subjects:

    • Understanding of the study and written informed consent prior to any study-related procedures
  • Additional inclusion criteria for healthy subjects:

    • Age: 18 to 65 years (inclusive) at screening visit
    • Males
    • Non- or ex-smokers who smoked < 5 pack-years and stopped smoking > 1 year prior to screening visit
    • Results of laboratory tests within the normal ranges; minor deviations are acceptable provided that they are not judged clinically significant by the investigator
  • Additional inclusion criteria for patients with COPD (chronic obstructive pulmonary disease):

    • Age: 40 to 70 years (inclusive) at screening visit
    • Males and females
    • All patients must have a diagnosis of COPD of Stage II or III according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) Classification (post-bronchodilator forced expiratory volume in 1 second (FEV1): 80% > FEV1 ≥ 30% of predicted values and a post-bronchodilator FEV1/FVC ≤ 70% (FVC = forced vital capacity)
    • Minimum smoking history of 10 pack-years
  • Additional inclusion criteria for patients with bronchiectasis:

    • Age: 18 to 75 years (inclusive) at screening visit
    • Males and females
    • Diagnosis of bronchiectasis

Exclusion Criteria:

  • Known hypersensitivity, allergy or intolerance to study drug formulation ingredients
  • Febrile illness within 1 week prior to screening visit
  • Concomitant severe diseases (judged by the investigator) or diseases which are contraindications for the use of inhaled ciprofloxacin
  • Use of ciprofloxacin within 30 days before screening visit
  • Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them, e.g. systemic administration of antibiotics which are subject to renal excretion (e.g. beta-lactam antibiotics, levofloxacin, ofloxacin, etc.), furosemide and antacids
  • Donation of more than 450 mL of blood within 4 weeks before screening visit
  • Clinically relevant findings in the ECG
  • Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation
  • Participation in another clinical study less than 8 weeks prior to screening visit
  • Pulmonary exacerbation within the 6 weeks prior to screening
  • History of lung transplant or any lung surgery or on any thoracic surgery waiting list
  • Additional exclusion criteria for healthy subjects

    • Lung function measurements outside normal limits (Normal values: FEV1/FVC > 70% and FEV1 and FVC > 80% of predicted)
  • Additional exclusion criteria for patients

    • Regular use of daytime oxygen therapy
    • Diagnosis of bronchial asthma
    • Diagnosis of clinically evident bronchiectasis (COPD patients)
    • Total blood eosinophil count >/= 600/mm3.
    • Completion of a pulmonary rehabilitation program in the six weeks prior to screening visit or current participation in a pulmonary rehabilitation program
    • Change in dose or type of any medications within 4 weeks prior to the screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01538667

Locations
Germany
Gauting, Bayern, Germany, 82131
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01538667     History of Changes
Other Study ID Numbers: 11523, 2011-000342-38
Study First Received: February 21, 2012
Last Updated: August 20, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Bayer:
Lung
Scintigraphy
Pharmacokinetics
Inhalation
Ciprofloxacin

Additional relevant MeSH terms:
Ciprofloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 28, 2014